

Richard J Lin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2794507/publications.pdf>

Version: 2024-02-01

94
papers

6,588
citations

304743

22
h-index

95266

68
g-index

95
all docs

95
docs citations

95
times ranked

5994
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Nuclear Receptor Coactivator ACTR Is a Novel Histone Acetyltransferase and Forms a Multimeric Activation Complex with P/CAF and CBP/p300. <i>Cell</i> , 1997, 90, 569-580. | 28.9 | 1,400 |
| 2 | Nuclear Receptor Repression Mediated by a Complex Containing SMRT, mSin3A, and Histone Deacetylase. <i>Cell</i> , 1997, 89, 373-380. | 28.9 | 1,206 |
| 3 | Role of the histone deacetylase complex in acute promyelocytic leukaemia. <i>Nature</i> , 1998, 391, 811-814. | 27.8 | 1,063 |
| 4 | Regulation of Hormone-Induced Histone Hyperacetylation and Gene Activation via Acetylation of an Acetylase. <i>Cell</i> , 1999, 98, 675-686. | 28.9 | 626 |
| 5 | Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. <i>New England Journal of Medicine</i> , 2020, 382, 822-834. | 27.0 | 435 |
| 6 | Acquisition of Oncogenic Potential by RAR Chimeras in Acute Promyelocytic Leukemia through Formation of Homodimers. <i>Molecular Cell</i> , 2000, 5, 821-830. | 9.7 | 223 |
| 7 | The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. <i>Nucleic Acids Research</i> , 1998, 26, 4645-4651. | 14.5 | 216 |
| 8 | Transcriptional regulation in acute promyelocytic leukemia. <i>Oncogene</i> , 2001, 20, 7204-7215. | 5.9 | 153 |
| 9 | Paraneoplastic thrombocytosis: the secrets of tumor self-promotion. <i>Blood</i> , 2014, 124, 184-187. | 1.4 | 137 |
| 10 | Constitutive Activation of Transcription and Binding of Coactivator by Estrogen-Related Receptors 1 and 2. <i>Molecular Endocrinology</i> , 1999, 13, 2151-2162. | 3.7 | 135 |
| 11 | Molecular genetics of acute promyelocytic leukemia. <i>Trends in Genetics</i> , 1999, 15, 179-184. | 6.7 | 107 |
| 12 | Hypoxia-induced transcriptional repression of the melanoma-associated oncogene <i>MITF</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, E924-33. | 7.1 | 101 |
| 13 | Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. <i>Blood Advances</i> , 2020, 4, 4669-4678. | 5.2 | 64 |
| 14 | Impact of <i>TP53</i> Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 369-381. | 1.6 | 60 |
| 15 | Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with <i>TP53</i> alterations. <i>British Journal of Haematology</i> , 2019, 184, 1006-1010. | 2.5 | 56 |
| 16 | Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes. <i>Blood Advances</i> , 2020, 4, 2810-2820. | 5.2 | 47 |
| 17 | Impact of geriatric vulnerabilities on allogeneic hematopoietic cell transplantation outcomes in older patients with hematologic malignancies. <i>Bone Marrow Transplantation</i> , 2020, 55, 157-164. | 2.4 | 39 |
| 18 | Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma. <i>Haematologica</i> , 2020, 106, 255-258. | 3.5 | 38 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2017, 130, 2180-2185. | 1.4 | 35 |
| 20 | Dyspnea in Palliative Care: Expanding the Role of Corticosteroids. <i>Journal of Palliative Medicine</i> , 2012, 15, 834-837. | 1.1 | 31 |
| 21 | Anemia in General Medical Inpatients Prolongs Length of Stay and Increases 30-Day Unplanned Readmission Rate. <i>Southern Medical Journal</i> , 2013, 106, 316-320. | 0.7 | 27 |
| 22 | Burden and impact of multifactorial geriatric syndromes in allogeneic hematopoietic cell transplantation for older adults. <i>Blood Advances</i> , 2019, 3, 12-20. | 5.2 | 27 |
| 23 | The Barriers to High-Quality Inpatient Pain Management. <i>American Journal of Hospice and Palliative Medicine</i> , 2015, 32, 594-599. | 1.4 | 25 |
| 24 | Therapeutic Anticoagulation in Patients with Primary Brain Tumors or Secondary Brain Metastasis. <i>Oncologist</i> , 2018, 23, 468-473. | 3.7 | 25 |
| 25 | A Phase II Study of Prophylactic Anakinra to Prevent CRS and Neurotoxicity in Patients Receiving CD19 CAR T Cell Therapy for Relapsed or Refractory Lymphoma. <i>Blood</i> , 2021, 138, 96-96. | 1.4 | 24 |
| 26 | Pretransplant comprehensive geriatric assessment in hematopoietic cell transplantation: a single center experience. <i>Bone Marrow Transplantation</i> , 2018, 53, 1184-1187. | 2.4 | 21 |
| 27 | Development of highly aggressive mantle cell lymphoma after sofosbuvir treatment of hepatitis C. <i>Blood Cancer Journal</i> , 2016, 6, e402-e402. | 6.2 | 20 |
| 28 | Allogeneic hematopoietic cell transplantation for older patients. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 254-263. | 2.5 | 18 |
| 29 | A Novel Role for Microphthalmia-Associated Transcription Factor-Regulated Pigment Epithelium-Derived Factor during Melanoma Progression. <i>American Journal of Pathology</i> , 2015, 185, 252-265. | 3.8 | 17 |
| 30 | The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT. <i>Blood Advances</i> , 2022, 6, 1525-1535. | 5.2 | 17 |
| 31 | Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 771.e1-771.e10. | 1.2 | 17 |
| 32 | The sentinel hospitalization and the role of palliative care. <i>Journal of Hospital Medicine</i> , 2014, 9, 320-323. | 1.4 | 16 |
| 33 | Potentially inappropriate medication use in elderly non-Hodgkin lymphoma patients is associated with reduced survival and increased toxicities. <i>British Journal of Haematology</i> , 2018, 180, 267-270. | 2.5 | 12 |
| 34 | Racial disparities in access to alternative donor allografts persist in the era of "donors for all". <i>Blood Advances</i> , 2022, 6, 5625-5629. | 5.2 | 12 |
| 35 | Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent Waves. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 438.e1-438.e6. | 1.2 | 11 |
| 36 | Lenalidomide for the Treatment of Cryoglobulinemia and Undifferentiated Spondyloarthritis in a Patient With Multiple Myeloma. <i>Journal of Clinical Rheumatology</i> , 2010, 16, 90-91. | 0.9 | 9 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Quality Assessment of Acute Inpatient Pain Management in an Academic Health Center. <i>American Journal of Hospice and Palliative Medicine</i> , 2016, 33, 16-19. | 1.4 | 9 |
| 38 | The geriatric syndrome of sarcopenia impacts allogeneic hematopoietic cell transplantation outcomes in older lymphoma patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 1833-1841. | 1.3 | 9 |
| 39 | End-of-life care for older AML patients relapsing after allogeneic stem cell transplant at a dedicated cancer center. <i>Bone Marrow Transplantation</i> , 2019, 54, 700-706. | 2.4 | 8 |
| 40 | Evidence-Based Minireview: Longitudinal geriatric assessment in quality care for older patients with hematologic malignancies. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 59-62. | 2.5 | 7 |
| 41 | Feasibility of a patient-reported, electronic geriatric assessment tool in hematopoietic cell transplantation – a single institution pilot study. <i>Leukemia and Lymphoma</i> , 2019, 60, 3308-3311. | 1.3 | 6 |
| 42 | Immune Reconstitution in the Aging Host: Opportunities for Mechanism-Based Therapy in Allogeneic Hematopoietic Cell Transplantation. <i>Frontiers in Immunology</i> , 2021, 12, 674093. | 4.8 | 6 |
| 43 | Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2108-2117. | 2.4 | 6 |
| 44 | Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma. <i>Haematologica</i> , 2022, 107, 1144-1152. | 3.5 | 6 |
| 45 | An unusual cause of chest pain: <i>Mycobacterium avium</i> complex and the immune reconstitution inflammatory syndrome. <i>Journal of Hospital Medicine</i> , 2011, 6, 309-311. | 1.4 | 5 |
| 46 | Cognitive Impairment Is Associated with Inferior Survival and Increased Non-Relapse Mortality in Older Allogeneic Hematopoietic Cell Transplant (alloHCT) Recipients: A Multicenter Retrospective Study. <i>Blood</i> , 2019, 134, 4606-4606. | 1.4 | 5 |
| 47 | Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 1603-1603. | 1.4 | 5 |
| 48 | Hematopoietic Cell Transplantation is Feasible in Patients with Prior COVID-19 Infection. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 55.e1-55.e5. | 1.2 | 5 |
| 49 | Paraneoplastic Autoimmunity Associated with Testicular Myeloid Sarcoma and Chronic Myelomonocytic Leukemia. <i>Case Reports in Hematology</i> , 2013, 2013, 1-4. | 0.4 | 4 |
| 50 | A Mixed-Methods Study of Pain-related Quality of Life in Sickle Cell Vaso-Occlusive Crises. <i>Hemoglobin</i> , 2015, 39, 305-309. | 0.8 | 4 |
| 51 | PEComa with Transcription Factor E3 Overexpression: A Diagnostic and Therapeutic Challenge. <i>Case Reports in Oncology</i> , 2017, 10, 531-533. | 0.7 | 4 |
| 52 | Transplant Physicians' Attitudes on Candidacy for Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Patients: The Need for a Standardized Geriatric Assessment (GA) Tool. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S45-S46. | 2.0 | 4 |
| 53 | Geriatric syndromes in 2-year, progression-free survivors among older recipients of allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 289-292. | 2.4 | 4 |
| 54 | Back to basics. <i>Clinical Teacher</i> , 2013, 10, 56-57. | 0.8 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Allogeneic Hematopoietic Cell Transplantation for Therapy-Related Myeloid Leukemia following Orthotopic Cardiac Transplantation. <i>Case Reports in Hematology</i> , 2013, 2013, 1-3. | 0.4 | 2 |
| 56 | The Role of Palliative Care in Medical Education. <i>Annals of Internal Medicine</i> , 2013, 159, 848-849. | 3.9 | 2 |
| 57 | Allogeneic Stem Cell Transplantation Overcomes the Negative Prognostic Impact of TP53 Alterations in Mantle Cell Lymphoma. <i>Blood</i> , 2018, 132, 4668-4668. | 1.4 | 2 |
| 58 | Pre-Transplant Fecal Microbial Diversity Independently Predicts Critical Illness after Hematopoietic Cell Transplantation. <i>Blood</i> , 2019, 134, 3264-3264. | 1.4 | 2 |
| 59 | The Biological Response to Biologics. <i>Science Translational Medicine</i> , 2011, 3, . | 12.4 | 2 |
| 60 | Authors' Reply. <i>American Journal of Pathology</i> , 2015, 185, 2070. | 3.8 | 1 |
| 61 | Prevalence and Characteristics of Caregiver Distress One-Year after Allogeneic Hematopoietic Cell Transplant in an Older Cohort of Patients - a Single Institution Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S77. | 2.0 | 1 |
| 62 | Feasibility and Clinical Utility of Electronic Geriatric Assessment (eGA) in Older Patients Undergoing Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S141-S142. | 2.0 | 1 |
| 63 | Characteristics of Peri-Transplant Palliative Supportive Care Consultation Among Older Allogeneic Hematopoietic Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S134. | 2.0 | 1 |
| 64 | Characteristics and Impact of Post-Transplant Interdisciplinary Palliative Care Consultation in Older Allogeneic Hematopoietic Cell Transplant Recipients. <i>Journal of Palliative Medicine</i> , 2020, 23, 1653-1657. | 1.1 | 1 |
| 65 | Ankyring the Heart Rhythm. <i>Science Translational Medicine</i> , 2011, 3, . | 12.4 | 1 |
| 66 | A Simple Geriatric Vulnerability Index for Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2018, 132, 2176-2176. | 1.4 | 1 |
| 67 | Antibodies on the Brain. <i>Science Translational Medicine</i> , 2012, 4, . | 12.4 | 1 |
| 68 | Commentary on "Primary Care Providers'™ Comfort Levels in Caring for Patients With Sickle Cell Disease". <i>Southern Medical Journal</i> , 2015, 108, 537-538. | 0.7 | 1 |
| 69 | My Very First Narcotics Prescription. <i>Journal of Palliative Medicine</i> , 2011, 14, 1178-1179. | 1.1 | 0 |
| 70 | Away from Home. <i>Journal of Palliative Medicine</i> , 2012, 15, 1392-1393. | 1.1 | 0 |
| 71 | Commentary on "Relation Between Prefracture Characteristics and Perioperative Complications in the Elderly Adult Patient With Hip Fracture". <i>Southern Medical Journal</i> , 2012, 105, 311-312. | 0.7 | 0 |
| 72 | Silence. <i>Academic Medicine</i> , 2013, 88, 1895. | 1.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | A road less traveled. <i>Kidney International</i> , 2014, 86, 862. | 5.2 | 0 |
| 74 | Prevalence of Functional Impairment and Geriatric Vulnerability during Pre-Transplant Geriatric Assessment in an Academic Hematopoietic Cell Transplantation Center. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S287-S288. | 2.0 | 0 |
| 75 | Impact of Pre-Transplant Measurable Residual Disease on Relapse Incidence and Progression-Free Survival in Older AML/MDS Patients Following Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S114. | 2.0 | 0 |
| 76 | Hematopoietic-cell transplantation for lymphoma in the era of genetically engineered cellular therapy: it's not quite time to scrap the old vehicle for the new car. <i>Current Opinion in Hematology</i> , 2019, 26, 288-293. | 2.5 | 0 |
| 77 | Favorable long-term outcomes of hematopoietic stem cell transplantation for CMML with myeloablative conditioning, anti-thymocyte globulin, and CD34+ selected graft. <i>Bone Marrow Transplantation</i> , 2020, 55, 1632-1634. | 2.4 | 0 |
| 78 | Don't Let the HCT-CI Fool You: Similar Outcomes with Myeloablative CD34+ Selected Allo-HCT Compared to Unmodified RIC Allo-HCT in Patients with AML or MDS and High Comorbidity Scores.. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S152-S153. | 2.0 | 0 |
| 79 | Impact of allogeneic hematopoietic cell transplantation on immune evasive mechanisms in relapsed refractory large B-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2020, 55, 2331-2334. | 2.4 | 0 |
| 80 | The Impact of Individual Co-Morbidities in Myeloablative Ex Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S141. | 2.0 | 0 |
| 81 | Long-Term Survival in Patients with AML or MDS Relapsed after Allogeneic Hematopoietic Cell Transplantation: Importance of Second Cell Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S97-S98. | 2.0 | 0 |
| 82 | Burden and Impact of Geriatric Syndromes in 2-Year, Progression-Free Survivors of Older Allogeneic Hematopoietic Cell Transplant Recipients – a Landmark Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S64-S65. | 2.0 | 0 |
| 83 | Toward the Future of Personalized Medicine. <i>Science Translational Medicine</i> , 2011, 3, . | 12.4 | 0 |
| 84 | Molecular Cancer Screening Comes Alive. <i>Science Translational Medicine</i> , 2011, 3, . | 12.4 | 0 |
| 85 | Breathing Easier. <i>Science Translational Medicine</i> , 2011, 3, . | 12.4 | 0 |
| 86 | E-Cadherin and the Esophagus. <i>Science Translational Medicine</i> , 2011, 3, . | 12.4 | 0 |
| 87 | Genomic Medicine at Its Best. <i>Science Translational Medicine</i> , 2011, 3, . | 12.4 | 0 |
| 88 | Too Much of a Good Thing. <i>Science Translational Medicine</i> , 2011, 3, . | 12.4 | 0 |
| 89 | Molecular Clue to Disease Prognosis. <i>Science Translational Medicine</i> , 2011, 3, . | 12.4 | 0 |
| 90 | Genetic Markers of In-Stent Thrombosis. <i>Science Translational Medicine</i> , 2011, 3, . | 12.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 91 | Whatâ€™s at the â€œFootâ€ of Kidney Disease?. Science Translational Medicine, 2011, 3, . | 12.4 | 0 |
| 92 | The Holy Grail of Hepatitis C Treatment. Science Translational Medicine, 2012, 4, . | 12.4 | 0 |
| 93 | Burden and Impact of Geriatric Syndromes Associated with Allogeneic Hematopoietic Cell Transplantation in Older Adults. Blood, 2018, 132, 3370-3370. | 1.4 | 0 |
| 94 | The Geriatric Syndrome of Sarcopenia Impacts Allogeneic Hematopoietic Cell Transplantation Outcomes in Combination with Multi-Morbidity and Functional Impairment. Blood, 2019, 134, 4508-4508. | 1.4 | 0 |